YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction

Socinski, 2013, Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-base Clinical Practice Guidelines, Chest, 143, e341s, 10.1378/chest.12-2361 Johnso, 2014, Recent clinical advances in lung cancer management, J. Clin. Oncol., 32, 973, 10.1200/JCO.2013.53.1228 Pao, 2010, Rational biologically based treatment of EGFR-mutant non-small-cell lung cancer, Nat. Rev. Cancer, 10, 760, 10.1038/nrc2947 Cataldo, 2011, Treatment of non-small-cell lung cancer with erlotinib or gefitinib, N. Engl. J. Med., 364, 947, 10.1056/NEJMct0807960 Cadranel, 2013, Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma, Crit. Rev. Oncol. Hematol., 88, 477, 10.1016/j.critrevonc.2013.06.009 Wu, 2018, Management of acquired resistance to EGFR TKI-target therapy in advanced non-small cell lung cancer, Mol. Cancer, 17, 38, 10.1186/s12943-018-0777-1 Garassino, 2013, Erlotinib versus decetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumor (TAILOR): a randomized controlled trial, Lancet Oncol., 14, 981, 10.1016/S1470-2045(13)70310-3 Shepherd, 2005, Erlotinib in previously treated non-small cell lung cancer, N. Engl. J. Med., 353, 123, 10.1056/NEJMoa050753 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Yano, 2008, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations, Cancer Res., 68, 9479, 10.1158/0008-5472.CAN-08-1643 Takezawa, 2012, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutation lung cancers that lack the second-site EGFR T790M mutation, Cancer Discov., 2, 922, 10.1158/2159-8290.CD-12-0108 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002003 Sos, 2009, PTEN loss contributes to erlotinib resistance is EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res., 69, 3256, 10.1158/0008-5472.CAN-08-4055 Oser, 2015, Transformation from non-mall-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, Lancet Oncol., 16, e165, 10.1016/S1470-2045(14)71180-5 Furg, 2012, EGFR tyrosine kinase inhibition induces autophagy in cancer cells, Cancer Biol. Ther., 13, 1417, 10.4161/cbt.22002 Gorzalczany, 2011, Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small lung cancer, Cancer Lett., 310, 207, 10.1016/j.canlet.2011.07.002 Li, 2013, Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer, Lung Cancer, 81, 354, 10.1016/j.lungcan.2013.05.012 Han, 2011, EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells, PLoS One, 6, 10.1371/journal.pone.0018691 Glick, 2010, Autophagy: cellular and molecular mechanisms, J. Pathol., 221, 3, 10.1002/path.2697 Mathew, 2007, Role of autophagy in cancer, Autophagy, 7, 28 White, 2011, The double-edged sword of autophagy modulation in cancer, Clin. Cancer Res., 15, 5308, 10.1158/1078-0432.CCR-07-5023 Amaravadi, 2007, The role of therapy-induced autophagy and necrosis in cancer treatment, Clin. Cancer Res., 13, 7271, 10.1158/1078-0432.CCR-07-1595 Chen, 2010, Autophagy is a therapeutic target in anticancer drug resistance, Biochim. Biophys. Acta, 1806, 220 Apel, 2008, Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy, Cancer Res., 68, 1485, 10.1158/0008-5472.CAN-07-0562 Altieri, 2008, Survivin, cancer networks and pathway-directed drug discovery, Nat. Rev. Cancer, 61, 10.1038/nrc2293 Nakahara, 2007, YM155, a novel small-molecule survivin suppressant induces regression of established human hormone-refractory prostate tumor xenograft, Cancer Res., 67, 8014, 10.1158/0008-5472.CAN-07-1343 Wang, 2011, Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells, Cancer Lett., 302, 29, 10.1016/j.canlet.2010.12.007 Wang, 2014, Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma, Apoptosis, 19, 748, 10.1007/s10495-013-0960-1 Okamoto, 2012, Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting surviving, Mol. Cancer Ther., 11, 204, 10.1158/1535-7163.MCT-11-0638 Dai, 2015, RNA interferences targeting the Fanconi Anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells, J. Biomed. Sci., 22, 77, 10.1186/s12929-015-0185-4 Dai, 2016, Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival, Oncotarget, 7, 65157, 10.18632/oncotarget.11214 Jiang, 2017, Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells, J. Cell. Physiol., 232, 3433, 10.1002/jcp.25792 Glaros, 2012, The “survivin suppressant” NSC 80467 and YM155 induce a DNA damage response, Cancer Chemother. Pharmacol., 70, 207, 10.1007/s00280-012-1868-0 Winter, 2014, The solute carrier SLC 35 F2 enables YM155-mediated DNA damage toxicity, Nat. Chem. Biol., 10, 768, 10.1038/nchembio.1590 Chang, 2015, YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway, J. Hematol. Oncol., 8, 29, 10.1186/s13045-015-0132-6 Paull, 2015, Mechanism of ATM activation, Annu. Rev. Biochem., 84, 711, 10.1146/annurev-biochem-060614-034335 Jazayeri, 2006, ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand break, Nat. Cell Biol., 8, 37, 10.1038/ncb1337 White, 2006, KAP1, a novel substrate for PIKK family members, colocalizes with numerous damage response factors at DNA lesions, Cancer Res., 66, 11594, 10.1158/0008-5472.CAN-06-4138 Lewis, 2011, A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma, Investig. New Drugs, 29, 161, 10.1007/s10637-009-9333-6 Tolcher, 2012, A phase II study of YM155, a novel small-molecule suppressor of survivin in castration-resistant taxane-pretreated prostate cancer, Ann. Oncol., 23, 968, 10.1093/annonc/mdr353 Giaccon, 2009, Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small cell lung cancer, J. Clin. Oncol., 27, 4481, 10.1200/JCO.2008.21.1862 Kelly, 2013, A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer, Ann. Oncol., 24, 2601, 10.1093/annonc/mdt249 Okamoto, 2010, Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancer positive for EGFR mutation, Cancer Res., 70, 10402, 10.1158/0008-5472.CAN-10-2438 Roca, 2008, CCL2 protects prostate PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation, J. Biol. Chem., 283, 25057, 10.1074/jbc.M801073200 Fimia, 2010, Regulation of autophagy in mammals and its interplay with apoptosis, Cell. Mol. Life Sci., 67, 1581, 10.1007/s00018-010-0284-z Erlich, 2007, Differential interactions between Beclin 1 and Bcl-2 family member, Autophagy, 3, 561, 10.4161/auto.4713 Pattingre, 2005, Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy, Cell, 122, 927, 10.1016/j.cell.2005.07.002 Niu, 2010, Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis, FEBS Lett., 584, 3519, 10.1016/j.febslet.2010.07.018 Kim, 2011, AMPK and mTOR regulate autophagy through direct phosphorylation of UIK1, Nat. Cell Biol., 13, 132, 10.1038/ncb2152 Oh, 2008, Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression, Clin. Cancer Res., 14, 1581, 10.1158/1078-0432.CCR-07-0952